|
List Of Miscellaneous Designer Cannabinoids
Since the first synthetic cannabinoids were discovered in recreational drug products in 2008, new synthetic cannabinoids with no precedent in the scientific literature continue to be identified. These synthetic cannabinoids appear to be rationally designed by clandestine medicinal chemists. These unprecedented synthetic cannabinoids often feature alphanumeric code names intended to mimic the style of chemical nomenclature used by academic laboratories and pharmaceutical companies, and there is generally little, if any, information available regarding their pharmacology and toxicology at the time of first discovery. * 5F-AB-PINACA — the terminally fluorinated (5-fluoropentyl) analogue of AB-PINACA. * 5F-AMB — * 5F-ADB — * 5F-NNE1 — * 5F-PCN — * 5F-SDB-006 — the terminally fluorinated (5-fluoropentyl) analogue of SDB-006. * AB-001 — one of the earliest adamantane derivatives discovered as a designer cannabinoid. AB-001 was unknown in the ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5F-AB-PINACA
5F-AB-PINACA is an indazole-based synthetic cannabinoid that is derived from a series of compounds originally developed by Pfizer in 2009 as an analgesic medication, and has been sold online as a designer drug. 5F-AB-PINACA has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.48 nM and 2.6 nM respectively. Its metabolism has been described in literature. Legality China As of October 2015 5F-AB-PINACA is a controlled substance in China. Germany 5F-AB-PINACA is an Anlage II controlled substance in Germany as of May 2015. Singapore It is also controlled under the Fifth Schedule of the Misuse of Drugs Act (MDA) in Singapore as of May 2015. See also * 5F-ADB * 5F-AMB * 5F-CUMYL-PINACA * AB-FUBINACA * AB-CHFUPYCA * AB-PINACA * ADB-CHMINACA * ADB-FUBINACA * ADB-PINACA * ADBICA * APICA * APINACA * MDMB-CHMICA * PX-3 PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agon ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
BIM-018
BIM-018 is a synthetic cannabinoid that is the benzimidazole analog of JWH-018. It is presumed to be a potent agonist of the CB2 receptor and has been sold online as a designer drug. Related benzimidazole derivatives have been reported to be highly selective agonists for the CB2 receptor. See also * AM-2201 * AZD-1940 * AZ-11713908 * FUBIMINA * MCHB-1 * THJ-018 * THJ-2201 THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is a structural analog of AM-2201 in which the central indole ring has been replac ... References Benzimidazoles Cannabinoids Designer drugs {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
NNE1
NNE1 (also known as NNEI, MN-24 and AM-6527) is an indole-based synthetic cannabinoid, representing a molecular hybrid of APICA and JWH-018 that is an agonist for the cannabinoid receptors, with ''K''i values of 60.09 nM at CB1 and 45.298 nM at CB2 and EC50 values of 9.481 nM at CB1 and 1.008 nM at CB2. It was invented by Abbott and has a CB1 receptor pEC50 of 8.9 with around 80x selectivity over the related CB2 receptor. It is suspected that metabolic hydrolysis of the amide group of NNE1 may release 1-naphthylamine, a known carcinogen, given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, and NNE1 was banned in New Zealand in 2012 as a temporary class drug to stop it being used as an ingredient in then-legal synthetic cannabis products. NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014. See also * 5F-NNE1 * 5F-PCN * AM-2201 * APICA * CUMYL-PICA * FDU-NNE ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MN-18
MN 18 is an indazole-based synthetic cannabinoid that is an agonist for the cannabinoid receptors, with ''K''i values of 45.72 nM at CB1 and 11.098 nM at CB2 and EC50 values of 2.028 nM at CB1 and 1.233 nM at CB2, and has been sold online as a designer drug. It is the indazole core analogue of NNE1. Given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, it is suspected that metabolic hydrolysis of the amide group of MN-18 may release 1-naphthylamine, a known carcinogen. MN-18 metabolism has been described in literature. Legal status MN-18 is banned in Sweden. On 15 September 2014 the Turkey government banned the sale of MN-18. See also * 5F-NNE1 * 5F-PB-22 * AM-2201 * BB-22 * FUB-JWH-018 * AB-FUBINACA * ADB-FUBINACA * AMB-FUBINACA * FDU-PB-22 * FUB-144 * FUB-APINACA * FUB-PB-22 * MDMB-FUBICA * MDMB-FUBINACA * PB-22 PB-22 (QUPIC, SGT-21 or 1-pentyl-1''H''-indole-3-carboxylic acid 8-quinoli ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MMB-2201
MMB-2201 (also known as 5F-MMB-PICA, 5F-AMB-PICA, and I-AMB) is a potent indole-3-carboxamide based synthetic cannabinoid, which has been sold as a designer drug and as an active ingredient in synthetic cannabis blends. It was first reported in Russia and Belarus in January 2014, but has since been sold in a number of other countries. In the United States, MMB-2201 was identified in Drug Enforcement Administration drug seizures for the first time in 2018. MMB-2201 is the indole core analogue of 5F-AMB. Synthetic cannabinoid compounds with an indole-3-carboxamide or indazole-3-carboxamide core bearing a ''N''-1-methoxycarbonyl group with attached isopropyl or ''tert''-butyl substituent, have proved to be much more dangerous than older synthetic cannabinoid compounds previously reported, and have been linked to many deaths in Russia, Japan, Europe and the United States. Legality MMB-2201 is illegal in Russia, Belarus and Sweden. See also * 5F-AB-PINACA * 5F-ADB * MDMB-CHMICA * MDM ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDMB-FUBINACA
MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with ''K''i values of 1.14 nM at CB1 and 0.1228 nM at CB2 and EC50 values of 0.2668 nM at CB1 and 0.1411 nM at CB2, and has been sold online as a designer drug. Its benzyl analogue (instead of 4-fluorobenzyl) has been reported to be a potent agonist for the CB1 receptor (''K''i = 0.14 nM, EC50 = 2.42 nM). The structure of MDMB-FUBINACA contains the amino aci3-methylvalineor tert-leucine methyl ester. Side effects There have been a large number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid, mainly in Russia and Belarus. MDMB-FUBINACA was first reported in 2014 and quickly gained a reputation as the most deadly synthetic cannabinoid drug sold by 2015. Up to 700 hospitalisations and 25 deaths were initially linked to MDMB-FUBINACA in media and govern ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDMB-CHMICA
MDMB-CHMICA is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA. Chemistry Several commercial samples of MDMB-CHMICA were found to exclusively contain the (''S'')-enantiomer based on vibrational and electronic circular dichroism spectroscopy and X-ray crystallography. An (S)-configuration for the ''tert''-leucinate group is unsurprising since MDMB-CHMICA is likely synthesized from the abundant and inexpensive "L" form of the appropriate ''tert''-leucinate reactant. Pharmacology MDMB-CHMICA acts as a highly potent full agonist of the CB1 receptor with an efficacy of 94% and an EC50 value of 0.14 nM, which is approximately 8 times lower than the EC ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FUBIMINA
FUBIMINA (also known as BIM-2201, BZ-2201 and FTHJ) is a synthetic cannabinoid that is the benzimidazole analog of AM-2201 and has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in 2013, alongside MEPIRAPIM. FUBIMINA acts as a reasonably potent agonist for the CB2 receptor ( ''K''i = 23.45 nM), with 12x selectivity over CB1 (''K''i = 296.1 nM), and does not fully substitute for Δ9-THC in rat discrimination studies. Related benzimidazole derivatives have been reported to be highly selective agonists for the CB2 receptor. See also * AM-694 * AM-1235 * AM-2232 * AM-2233 * BIM-018 * JWH-018 * List of AM cannabinoids * List of JWH cannabinoids * THJ-2201 THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is a structural analog of AM-2201 in which the central indole ring has been r ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
UR-144
UR-144 (TMCP-018, KM-X1, MN-001, YX-17) is a drug invented by Abbott Laboratories, that acts as a selective full agonist of the peripheral cannabinoid receptor CB2, but with much lower affinity for the psychoactive CB1 receptor. Pharmacology UR-144 has high affinity for the CB2 receptor with a Ki of 1.8 nM but 83x lower affinity for the CB1 receptor with a Ki of 150 nM. UR-144 was found to possess an EC50 of 421 nM for human CB1 receptors, and 72 nM for human CB2 receptors. UR-144 produces bradycardia and hypothermia in rats at a dose of 10 mg/kg, suggesting weak cannabinoid-like activity. Chemically it is closely related to other 2,2,3,3-tetramethylcyclopropyl synthetic cannabinoids like A-796,260 and A-834,735 but with a different substitution on the 1-position of the indole core, in these compounds its 1-pentyl group is replaced with alkylheterocycles like 1-(2-morpholinoethyl) and 1-(tetrahydropyran-4-ylmethyl). Legality The UK ACMD recommended that generic prohibiti ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FUB-144
FUB-144 (also known as FUB-UR-144) is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is an analogue of UR-144 and XLR-11 where the pentyl chain has been replaced with fluorobenzyl. Legal status In the United States, FUB-144 was temporarily emergency scheduled by the DEA in 2019. and made a permanent Schedule I Controlled Substance on April 7, 2022. Sweden's public health agency suggested classifying FUB-144 as hazardous substance on March 24, 2015. See also * A-834,735 * AB-005 AB-005 or -[(1-methylpiperidin-2-yl)methyl1''H''-indol-3-yl">1-methylpiperidin-2-yl)methyl.html" ;"title="-[(1-methylpiperidin-2-yl)methyl">-[(1-methylpiperidin-2-yl)methyl1''H''-indol-3-yl2,2,3,3-tetramethylcyclopropyl)-methanone is a designer ... * FAB-144 * JWH-018 * STS-135 (drug), STS-135 References {{Cannabinoids Cannabinoids Designer drugs Fluoroarenes Indoles [ ategory:Tetramethylcyclopr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FDU-NNE1
FDU-NNE1 (also known as FDU-NNEI and FDU-MN-24) is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. Given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, it is suspected that metabolic hydrolysis of the amide group of FDU-NNE1 will release 1-naphthylamine, a known carcinogen. See also * 5F-NNE1 * 5F-PB-22 * AM-2201 * BB-22 * FUB-JWH-018 * AB-FUBINACA * ADB-FUBINACA * AMB-FUBINACA * FUB-144 * FUB-APINACA * FUB-PB-22 * MDMB-FUBICA * MDMB-FUBINACA * NNE1 * PB-22 PB-22 (QUPIC, SGT-21 or 1-pentyl-1''H''-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in Japan in 2013. PB-22 represent ... References Designer drugs Fluoroarenes Indolecarboxamides Naphthoylindoles {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
XLR-11
XLR-11 (5"-fluoro-UR-144 or 5F-UR-144) is a drug that acts as a potent agonist for the cannabinoid receptors CB1 and CB2 with EC50 values of 98 nM and 83 nM, respectively. It is a 3-(tetramethylcyclopropylmethanoyl)indole derivative related to compounds such as UR-144, A-796,260 and A-834,735, but it is not specifically listed in the patent or scientific literature alongside these other similar compounds, and appears to have not previously been made by Abbott Laboratories, despite falling within the claims of patent WO 2006/069196. XLR-11 was found to produce rapid, short-lived hypothermic effects in rats at doses of 3 mg/kg and 10 mg/kg, suggesting that it is of comparable potency to APICA and STS-135. Detection A forensic standard for this compound is available, and a representative mass spectrum has been posted on Forendex. Recreational use XLR-11 was instead first identified by laboratories in 2012 as an ingredient in synthetic cannabis smoking blends, and ap ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |